Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer

由 Cleary, James M., Shapiro, Geoffrey I.
出版 2010

Biomarker-Guided Development of DNA Repair Inhibitors

由 Cleary, James M., Aguirre, Andrew J., Shapiro, Geoffrey I., D’Andrea, Alan D.
發表在 Mol Cell (2020)

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone

由 Cleary, James M., Rosen, Lee S., Yoshida, Kenichiro, Rasco, Drew, Shapiro, Geoffrey I., Sun, Weijing
發表在 Invest New Drugs (2017)

Update on the Role of Imaging in Management of Metastatic Colorectal Cancer

由 Tirumani, Sree Harsha, Kim, Kyung Won, Nishino, Mizuki, Howard, Stephanie A., Krajewski, Katherine M., Jagannathan, Jyothi P., Cleary, James M., Ramaiya, Nikhil H., Shinagare, Atul B.
發表在 Radiographics (2014)

A Phase II and Biomarker Study of Cabozantinib in Patients with Advanced Cholangiocarcinoma

由 Goyal, Lipika, Zheng, Hui, Yurgelun, Matthew B., Abrams, Thomas A., Allen, Jill N., Cleary, James M., Knowles, Michelle, Regan, Eileen, Reardon, Amanda, Khachatryan, Anna, Jain, Rakesh K., Nardi, Valentina, Borger, Darrell R., Duda, Dan G., Zhu, Andrew X.
發表在 Cancer (2017)

Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma

由 Wolpin, Brian M., Rubinson, Douglas A., Wang, Xiaoxu, Chan, Jennifer A., Cleary, James M., Enzinger, Peter C., Fuchs, Charles S., McCleary, Nadine J., Meyerhardt, Jeffrey A., Ng, Kimmie, Schrag, Deborah, Sikora, Allison L., Spicer, Beverly A., Killion, Leah, Mamon, Harvey, Kimmelman, Alec C.
出版 2014

High-throughput dynamic BH3 profiling (HT-DBP) may quickly and accurately predict effective therapies in solid tumors

由 Bhola, Patrick, Ahmed, Eman, Guerriero, Jennifer L., Sicinska, Ewa, Su, Emily, Lavrova, Elizaveta, Ni, Jing, Chipashvili, Otari, Hagan, Timothy, Pioso, Marissa S., McQueeney, Kelley, Ng, Kimmie, Aguirre, Andrew J., Cleary, James M., Cocozziello, David, Sotayo, Alaba, Ryan, Jeremy, Zhao, Jean J., Letai, Anthony
發表在 Sci Signal (2020)

Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer

由 Cleary, James M., Mamon, Harvey J., Szymonifka, Jackie, Bueno, Raphael, Choi, Noah, Donahue, Dean M., Fidias, Panos M., Gaissert, Henning A., Jaklitsch, Michael T., Kulke, Matthew H., Lynch, Thomas P., Mentzer, Steven J., Meyerhardt, Jeffrey A., Swanson, Richard S., Wain, John, Fuchs, Charles S., Enzinger, Peter C.
發表在 BMC Cancer (2016)

Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies

由 Mita, Monica M, Mita, Alain C, Moseley, Jennifer L, Poon, Jennifer, Small, Karen A, Jou, Ying-Ming, Kirschmeier, Paul, Zhang, Da, Zhu, Yali, Statkevich, Paul, Sankhala, Kamelesh K, Sarantopoulos, John, Cleary, James M, Chirieac, Lucian R, Rodig, Scott J, Bannerji, Rajat, Shapiro, Geoffrey I
發表在 Br J Cancer (2017)

AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results

由 Ng, Matthew C. H., Goyal, Lipika, Bang, Yung-Jue, Oh, Do-Youn, Chao, Tsu-Yi, Cleary, James M., Voss, Martin Henner, Meric-Bernstam, Funda, Iyer, Gopa, Heist, Rebecca Suk, Ishii, Nobuya, Kirpicheva, Yulia, Pokorska-Bocci, Anna, Vaslin, Anne, Hu, Youyou, Zanna, Claudio, Hyman, David, Flaherty, Keith
發表在 Hepatobiliary Surg Nutr (2019)

Genomic Evolution After Chemoradiotherapy in Anal Squamous Cell Carcinoma

由 Mouw, Kent W, Cleary, James M, Reardon, Brendan, Pike, Jonathan, Braunstein, Lior Z, Kim, Jaegil, Amin-Mansour, Ali, Miao, Diana, Damish, Alexis, Chin, Joanna, Ott, Patrick A., Fuchs, Charles, Martin, Neil, Getz, Gad, Carter, Scott, Mamon, Harvey J, Hornick, Jason L, Van Allen, Eliezer M, D’Andrea, Alan D
發表在 Clin Cancer Res (2016)

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

由 Razak, Albiruni RA, Cleary, James M, Moreno, Victor, Boyer, Michael, Calvo Aller, Emiliano, Edenfield, William, Tie, Jeanne, Harvey, R Donald, Rutten, Annemie, Shah, Manish A, Olszanski, Anthony J, Jäger, Dirk, Lakhani, Nehal, Ryan, David P, Rasmussen, Erik, Juan, Gloria, Wong, Hansen, Soman, Neelesh, Smit, Marie-Anne Damiette, Nagorsen, Dirk, Papadopoulos, Kyriakos P
發表在 J Immunother Cancer (2020)

Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study

由 Lowery, Maeve A, Burris, Howard A, Janku, Filip, Shroff, Rachna T, Cleary, James M, Azad, Nilofer S, Goyal, Lipika, Maher, Elizabeth A, Gore, Lia, Hollebecque, Antoine, Beeram, Muralidhar, Trent, Jonathan C, Jiang, Liewen, Fan, Bin, Aguado-Fraile, Elia, Choe, Sung, Wu, Bin, Gliser, Camelia, Agresta, Samuel V, Pandya, Shuchi S, Zhu, Andrew X, Abou-Alfa, Ghassan K
發表在 Lancet Gastroenterol Hepatol (2019)

Preemptive Versus Reactive Topical Clobetasol for Regorafenib‐Induced Hand‐Foot Reactions: A Preplanned Analysis of the ReDOS Trial

由 Jatoi, Aminah, Ou, Fang‐Shu, Ahn, Daniel H., Zemla, Tyler J., Le‐Rademacher, Jennifer G., Boland, Patrick, Ciombor, Kristen K., Jacobs, Nisha L., Pasche, Boris, Cleary, James M., McCune, Jeannine S., Pedersen, Katrina S., Barzi, Afsaneh, Chiorean, E. Gabriela, Heying, Erica N., Lenz, Heinz‐Josef, Sloan, Jeff A., Grothey, Axel, Lacouture, Mario E., Bekaii‐Saab, Tanios
發表在 Oncologist (2021)

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib

由 Wagle, Nikhil, Grabiner, Brian C., Van Allen, Eliezer M., Hodis, Eran, Jacobus, Susanna, Supko, Jeffrey G., Stewart, Michelle, Choueiri, Toni K., Gandhi, Leena, Cleary, James M., Elfiky, Aymen A., Taplin, Mary Ellen, Stack, Edward C., Signoretti, Sabina, Loda, Massimo, Shapiro, Geoffrey I., Sabatini, David, Lander, Eric S., Gabriel, Stacey B., Kantoff, Philip W., Garraway, Levi A., Rosenberg, Jonathan E.
出版 2014

Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with a...

由 LoRusso, Patricia M., Li, Jing, Burger, Angelika, Heilbrun, Lance K., Sausville, Edward A., Boerner, Scott A., Smith, Daryn, Pilat, Mary Jo, Zhang, Jie, Tolaney, Sara M., Cleary, James M., Chen, Alice P., Rubinstein, Lawrence, Boerner, Julie L., Bowditch, Adam, Cai, Dongpo, Bell, Tracy, Wolanski, Andrew, Marrero, Allison M., Zhang, Yiping, Ji, Jiuping, Ferry-Galow, Katherine, Kinders, Robert J., Parchment, Ralph E., Shapiro, Geoffrey I.
發表在 Clin Cancer Res (2016)

FOLFOX Plus Ziv-Aflibercept or Placebo in First-Line Metastatic Esophagogastric Adenocarcinoma: A Double-Blind, Randomized, Multicenter Phase 2 Trial

由 Cleary, James M., Horick, Nora K., McCleary, Nadine Jackson, Abrams, Thomas A., Yurgelun, Matthew B., Azzoli, Christopher G., Rubinson, Douglas A., Brooks, Gabriel A., Chan, Jennifer A., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Goyal, Lipika, Meyerhardt, Jeffrey A., Ng, Kimmie, Schrag, Deborah, Savarese, Diane M.F., Graham, Christopher, Fitzpatrick, Bridget, Gibb, Kathryn A., Boucher, Yves, Duda, Dan G., Jain, Rakesh K., Fuchs, Charles S., Enzinger, Peter C.
發表在 Cancer (2019)

Effect of High-Dose vs Standard-Dose Vitamin D(3) Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized...

由 Ng, Kimmie, Nimeiri, Halla S., McCleary, Nadine J., Abrams, Thomas A., Yurgelun, Matthew B., Cleary, James M., Rubinson, Douglas A., Schrag, Deborah, Miksad, Rebecca, Bullock, Andrea J., Allen, Jill, Zuckerman, Dan, Chan, Emily, Chan, Jennifer A., Wolpin, Brian M., Constantine, Michael, Weckstein, Douglas J., Faggen, Meredith A., Thomas, Christian A., Kournioti, Chryssanthi, Yuan, Chen, Ganser, Christine, Wilkinson, Brittney, Mackintosh, Christopher, Zheng, Hui, Hollis, Bruce W., Meyerhardt, Jeffrey A., Fuchs, Charles S.
發表在 JAMA (2019)

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

由 Abou-Alfa, Ghassan K, Macarulla, Teresa, Javle, Milind M, Kelley, Robin K, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V, Borad, Mitesh J, Bridgewater, John, Harris, William P, Murphy, Adrian G, Oh, Do-Youn, Whisenant, Jonathan, Lowery, Maeve A, Goyal, Lipika, Shroff, Rachna T, El-Khoueiry, Anthony B, Fan, Bin, Wu, Bin, Chamberlain, Christina X, Jiang, Liewen, Gliser, Camelia, Pandya, Shuchi S, Valle, Juan W, Zhu, Andrew X
發表在 Lancet Oncol (2020)

Effect of High-Dose vs Standard-Dose Vitamin D(3) Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial

由 Brown, Justin C., Rosenthal, Michael H., Ma, Chao, Zhang, Sui, Nimeiri, Halla S., McCleary, Nadine J., Abrams, Thomas A., Yurgelun, Matthew B., Cleary, James M., Rubinson, Douglas A., Schrag, Deborah, Bullock, Andrea J., Allen, Jill, Zuckerman, Dan, Chan, Emily, Chan, Jennifer A., Wolpin, Brian, Constantine, Michael, Weckstein, Douglas J., Faggen, Meredith A., Thomas, Christian A., Kournioti, Chryssanthi, Yuan, Chen, Zheng, Hui, Hollis, Bruce W., Fuchs, Charles S., Ng, Kimmie, Meyerhardt, Jeffrey A.
發表在 Cancers (Basel) (2020)